These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19823076)

  • 21. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
    Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
    Strawn LM; Kabbinavar F; Schwartz DP; Mann E; Shawver LK; Slamon DJ; Cherrington JM
    Clin Cancer Res; 2000 Jul; 6(7):2931-40. PubMed ID: 10914743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
    Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
    Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of ifosfamide in small cell lung cancer.
    Loehrer PJ
    Semin Oncol; 1996 Jun; 23(3 Suppl 7):40-4. PubMed ID: 8711501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
    Triller N; Korosec P; Kern I; Kosnik M; Debeljak A
    Lung Cancer; 2006 Nov; 54(2):235-40. PubMed ID: 16934363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
    Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
    Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
    J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.
    Némati F; Bras-Gonçalves R; Fontaine JJ; de Pinieux G; De Cremoux P; Chapelier A; Daniel C; Laurent-Puig P; Livartowski A; Judde JG; Bordier V; Poupon MF; Decaudin D
    Anticancer Drugs; 2009 Nov; 20(10):932-40. PubMed ID: 19741504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
    Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
    Dingemans AC; van Ark-Otte J; Span S; Scagliotti GV; van der Valk P; Postmus PE; Giaccone G
    Lung Cancer; 2001 May; 32(2):117-28. PubMed ID: 11325482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy of small cell lung cancer with emphasis on oral topotecan.
    Pirker R; Berzinec P; Brincat S; Kasan P; Ostoros G; Pesek M; Plāte S; Purkalne G; Rooneem R; Skricková J; Stanculeanu D; Timcheva C; Tzekova V; Zakotnik B; Zielinski CC; Zwitter M
    Lung Cancer; 2010 Oct; 70(1):7-13. PubMed ID: 20576312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
    Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
    J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
    Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
    Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of topotecan and cisplatin in patients with small cell lung cancer.
    Ichinose Y; Seto T; Nishiwaki Y; Kiura K; Sakai H; Yokoyama A; Segawa Y; Ando M; Watanabe K
    Jpn J Clin Oncol; 2011 Feb; 41(2):197-203. PubMed ID: 20937601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer.
    Han M; Dai J; Zhang Y; Lin Q; Jiang M; Xu X; Liu Q; Jia J
    Oncol Rep; 2012 Dec; 28(6):2233-8. PubMed ID: 22992788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.